Pyxis Oncology, Inc. (PYXS)

NASDAQ: PYXS · Real-Time Price · USD

1.040

-0.020 (-1.89%)

Apr 28, 2025, 4:00 PM EDT - Market closed

Pyxis Oncology Employees

Pyxis Oncology had 44 employees as of December 31, 2024. The number of employees decreased by 6 or -12.00% compared to the previous year.

Employees

44

Change (1Y)

-6

Growth (1Y)

-12.00%

Revenue / Employee

$366,955

Profits / Employee

-$1,757,523

Market Cap

64.05M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2024	44	-6	-12.00%
Dec 31, 2023	50	-25	-33.33%
Dec 31, 2022	75	19	33.93%
Dec 31, 2021	56	-	-

Related Stocks

Company Name	Employees
UnitedHealth Group	400,000
Johnson & Johnson	138,100
Thermo Fisher Scientific	125,000
Abbott Laboratories	114,000
AstraZeneca	92,900
Novartis AG	75,883
Merck & Co.	75,000
AbbVie	55,000

Employee Rankings

PYXS News

3 days ago - Pyxis Oncology Presents Promising Preclinical Results Providing Proof of Mechanism of Micvotabart Pelidotin, the First-in-Concept Extracellular-Targeting ADC - GlobeNewsWire
26 days ago - Pyxis Oncology to Participate in the Stifel 2025 Virtual Targeted Oncology Forum - GlobeNewsWire
4 weeks ago - Pyxis Oncology to Present New Preclinical Data Supporting Development of First-In-Concept ADC Targeting EDB+FN in Tumor Microenvironment at AACR 2025 - GlobeNewsWire
5 weeks ago - Pyxis Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - GlobeNewsWire
2 months ago - Pyxis Oncology to Participate at the Leerink Partners Global Healthcare Conference - GlobeNewsWire
2 months ago - Pyxis Oncology Granted FDA Fast Track Designation for PYX-201 Monotherapy in Patients with Recurrent or Metastatic Head and Neck Cancer - GlobeNewsWire
2 months ago - Pyxis Oncology Initiates New PYX-201 Combination Trial and Initiates Cohort Expansions of Ongoing Monotherapy Trial - GlobeNewsWire
4 months ago - Pyxis Oncology Announces Portfolio Prioritization, Focusing Resources on its Lead Clinical Program, PYX-201 - GlobeNewsWire